Cargando…

Development of a novel, high-affinity ssDNA trypsin inhibitor

Inhibitors of serine proteases are not only extremely useful in the basic research but are also applied extensively in clinical settings. Using Systematic Evolution of Ligands by Exponential Enrichment (SELEX) approach we developed a family of novel, single-stranded DNA aptamers capable of specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Malicki, Stanislaw, Ksiazek, Miroslaw, Majewski, Pawel, Pecak, Aleksandra, Mydel, Piotr, Grudnik, Przemyslaw, Dubin, Grzegorz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366424/
https://www.ncbi.nlm.nih.gov/pubmed/30727784
http://dx.doi.org/10.1080/14756366.2019.1569648
_version_ 1783393624330862592
author Malicki, Stanislaw
Ksiazek, Miroslaw
Majewski, Pawel
Pecak, Aleksandra
Mydel, Piotr
Grudnik, Przemyslaw
Dubin, Grzegorz
author_facet Malicki, Stanislaw
Ksiazek, Miroslaw
Majewski, Pawel
Pecak, Aleksandra
Mydel, Piotr
Grudnik, Przemyslaw
Dubin, Grzegorz
author_sort Malicki, Stanislaw
collection PubMed
description Inhibitors of serine proteases are not only extremely useful in the basic research but are also applied extensively in clinical settings. Using Systematic Evolution of Ligands by Exponential Enrichment (SELEX) approach we developed a family of novel, single-stranded DNA aptamers capable of specific trypsin inhibition. Our most potent candidate (T24) and its short version (T59) were thoroughly characterised in terms of efficacy. T24 and T59 efficiently inhibited bovine trypsin with K(i) of 176 nM and 475 nM, respectively. Interestingly, in contrast to the majority of known trypsin inhibitors, the selected aptamers have superior specificity and did not interact with porcine trypsin or any human proteases tested. These included plasmin and thrombin characterised by trypsin-like substrate specificity. Our results demonstrate that SELEX may be successfully employed in the development of potent and specific DNA based protease inhibitors.
format Online
Article
Text
id pubmed-6366424
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-63664242019-02-15 Development of a novel, high-affinity ssDNA trypsin inhibitor Malicki, Stanislaw Ksiazek, Miroslaw Majewski, Pawel Pecak, Aleksandra Mydel, Piotr Grudnik, Przemyslaw Dubin, Grzegorz J Enzyme Inhib Med Chem Short Communication Inhibitors of serine proteases are not only extremely useful in the basic research but are also applied extensively in clinical settings. Using Systematic Evolution of Ligands by Exponential Enrichment (SELEX) approach we developed a family of novel, single-stranded DNA aptamers capable of specific trypsin inhibition. Our most potent candidate (T24) and its short version (T59) were thoroughly characterised in terms of efficacy. T24 and T59 efficiently inhibited bovine trypsin with K(i) of 176 nM and 475 nM, respectively. Interestingly, in contrast to the majority of known trypsin inhibitors, the selected aptamers have superior specificity and did not interact with porcine trypsin or any human proteases tested. These included plasmin and thrombin characterised by trypsin-like substrate specificity. Our results demonstrate that SELEX may be successfully employed in the development of potent and specific DNA based protease inhibitors. Taylor & Francis 2019-02-06 /pmc/articles/PMC6366424/ /pubmed/30727784 http://dx.doi.org/10.1080/14756366.2019.1569648 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Malicki, Stanislaw
Ksiazek, Miroslaw
Majewski, Pawel
Pecak, Aleksandra
Mydel, Piotr
Grudnik, Przemyslaw
Dubin, Grzegorz
Development of a novel, high-affinity ssDNA trypsin inhibitor
title Development of a novel, high-affinity ssDNA trypsin inhibitor
title_full Development of a novel, high-affinity ssDNA trypsin inhibitor
title_fullStr Development of a novel, high-affinity ssDNA trypsin inhibitor
title_full_unstemmed Development of a novel, high-affinity ssDNA trypsin inhibitor
title_short Development of a novel, high-affinity ssDNA trypsin inhibitor
title_sort development of a novel, high-affinity ssdna trypsin inhibitor
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366424/
https://www.ncbi.nlm.nih.gov/pubmed/30727784
http://dx.doi.org/10.1080/14756366.2019.1569648
work_keys_str_mv AT malickistanislaw developmentofanovelhighaffinityssdnatrypsininhibitor
AT ksiazekmiroslaw developmentofanovelhighaffinityssdnatrypsininhibitor
AT majewskipawel developmentofanovelhighaffinityssdnatrypsininhibitor
AT pecakaleksandra developmentofanovelhighaffinityssdnatrypsininhibitor
AT mydelpiotr developmentofanovelhighaffinityssdnatrypsininhibitor
AT grudnikprzemyslaw developmentofanovelhighaffinityssdnatrypsininhibitor
AT dubingrzegorz developmentofanovelhighaffinityssdnatrypsininhibitor